Insight

Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer

Emmy Boerrigter/LinkedIn

Dec 30, 2024, 13:30

Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer

A recent paper by Emmy Boerrigter, Pharmacist at Radboudumc Research Institute for Medical Innovation, was mentioned by European Urology Oncology on X:

“A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with PCa by Emmy Boerrigter, Joanneke K. Overbeek et al.”

“A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer”

Authors: Emmy Boerrigter, Joanneke Overbeek, Guillemette Benoist, Inge van Oort, Nielka van Erp et al.

More posts featuring European Urology Oncology.

cancer Emmy Boerrigter European Urology Oncology Guillemette Benoist Inge van Oort Joanneke Overbeek Nielka van Erp OncoDaily Oncology prostate cancer

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more